Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK

Blackstone, James, Williams, Thomas, Nicholas, Jennifer M., Bordea, Ekaterina, De Angelis, Floriana, Bianchi, Alessia, Calvi, Alberto, Doshi, Anisha, John, Nevin, Apap Mangion, Sean, Wade, Charles, Merry, Rachel, Barton, Gil, Lyle, Dawn, Jarman, Elisabeth, Mahad, Don, Shehu, Abdullah, Arun, Tarunya, McDonnell, Gavin, Geraldes, Ruth, Craner, Matthew, Hillier, Charles, Ganesalingam, Jeban, Fisniku, Leonora, Hobart, Jeremy, Spilker, Cord, Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909, Kalra, Seema, Pluchino, Stefano, Harikrishnan, Sreedharan, Mattoscio, Miriam, Harrower, Timothy, Young, Carolyn, Lee, Martin, Chhetri, Suresh, Ahmed, Fayyaz, Rog, David, Silber, Eli, Gallagher, Paul, Duddy, Martin, Straukiene, Agne, Nicholas, Richard, Rice, Claire, Nixon, Stuart J., Beveridge, Judy, Hawton, Annie, Tebbs, Susan, Braisher, Marie, Giovannoni, Gavin, Ciccarelli, Olga, Greenwood, John, Thompson, Alan J., Hunter, Rachael, Pavitt, Sue, Pearson, Owen, Evangelou, Nikos, Sharrack, Basil, Galea, Ian, Chandran, Siddharthan, Ford, Helen L., Frost, Chris and Chataway, Jeremy 2024. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. BMJ Open 14 (9) , e086414. 10.1136/bmjopen-2024-086414

PDF - Published Version Available under License Creative Commons Attribution. Download (677kB)

Abstract

Introduction: There remains a high unmet need for disease-modifying therapies that can impact disability progression in secondary progressive multiple sclerosis (SPMS). Following positive results of the phase 2 MS-STAT study, the MS-STAT2 phase 3 trial will evaluate the efficacy and cost-effectiveness of repurposed high-dose simvastatin in slowing the progression of disability in SPMS. Methods and analysis: MS-STAT2 will be a multicentre, randomised, placebo-controlled, double-blind trial of participants aged between 25 and 65 (inclusive) who have SPMS with an Expanded Disability Status Scale (EDSS) score of 4.0–6.5 (inclusive). Steady progression rather than relapse must be the major cause of increasing disability in the preceding 2 years. Participants will be allocated to simvastatin or placebo in a 1:1 ratio. The active treatment will be 80 mg daily, after 1 month at 40 mg daily. 31 hospitals across the UK will participate. The primary outcome is (confirmed) disability progression at 6 monthly intervals, measured as change from EDSS baseline score. Recruitment of 1050 participants will be required to achieve a total of 330 progression events, giving 90% power to demonstrate a 30% relative reduction in disability progression versus placebo. The follow-up period is 36 months, extendable by up to 18 months for patients without confirmed progression. Clinician-reported measures include Timed 25 Foot Walk; 9 Hole Peg Test; Single Digit Modalities Test; Sloan Low Contrast Visual Acuity; Relapse assessment; modified Rankin Scale and Brief International Cognitive Assessment For Multiple Sclerosis. Patient-reported outcomes include MS-specific walking, fatigue and impact scales. A health economic analysis will occur. Ethics and dissemination: The protocol was approved by the London-Westminster REC (17/LO/1509). This manuscript is based on protocol version 8.0, 26 February 2024. Trial findings will be disseminated through peer-reviewed publications and conference presentations. Trial registration numbers: NCT03387670; ISRCTN82598726.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: https://creativecommons.org/licenses/by/4.0/, Start Date: 2024-09-16, Type: open-access
Publisher:	BMJ Publishing Group
Date of First Compliant Deposit:	18 September 2024
Date of Acceptance:	16 August 2024
Last Modified:	18 Sep 2024 09:30
URI:	https://orca.cardiff.ac.uk/id/eprint/172203

Actions (repository staff only)

Edit Item